Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risvutatug rezetecan in advanced gastrointestinal solid tumors
NCT06885034Phase 2Recruiting
- Sponsor
- GSK
- Start
- Jun 2025
- Primary completion
- Jan 2029
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 19
01
Overview
Phase 2, randomised, open-label trial of risvutatug rezetecan in colorectal adenocarcinoma and pancreatic adenocarcinoma (PDAC) (6 arms), sponsored by GSK. Primary endpoint: Confirmed Objective Response Rate. Started Jun 2025; status: recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
colorectal adenocarcinomapancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06885034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06885034.